PD-L1 on tumor cells has been the predictive biomarker of response to ICIs, however, its predictive value is not accurate as the PD-L1 tumor proportion score (TPS) groups might achieve significant survival benefits, including those with TPS <1% (7). The gene discussed is CD274; the disease is neoplasm.